WVE-003
RNA / oligonucleotide
Evidence outlook · no controlled comparison
SELECT-HD (NCT05032196) · Huntington's Disease
The lead study produced no formal comparison against a control: it had a single arm, or its primary endpoint did not compare the groups (for example, a safety count). This tier describes the design, not an outcome.
SELECT-HD (NCT05032196): This was a randomized, double-blind, placebo-controlled study in 47 patients, but its only primary measure was the number of patients with drug-related side effects, so it made no formal test of whether WVE-003 works. Drug-related side effects were seen in 1 of 13, 3 of 10 and 3 of 8 patients at single doses of 30, 60 and 90 mg against 2 of 16 on placebo. Its registered primary outcome on ClinicalTrials.gov is "Safety: Proportion of Patients With Treatment Emergent Adverse Events (TEAEs) Related to Study Drug". Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
SELECT-HD NCT05032196 · Huntington's Disease This was a randomized, double-blind, placebo-controlled study in 47 patients, but its only primary measure was the number of patients with drug-related side effects, so it made no formal test of whether WVE-003 works. Drug-related side effects were seen in 1 of 13, 3 of 10 and 3 of 8 patients at single doses of 30, 60 and 90 mg against 2 of 16 on placebo. Its registered primary outcome on ClinicalTrials.gov is "Safety: Proportion of Patients With Treatment Emergent Adverse Events (TEAEs) Related to Study Drug". Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak. Registry: NCT05032196 | 1/2 | Safety: Proportion of Patients With Treatment Emergent Adverse Events (TEAEs) Related to Study Drug (Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2)) 2024-05-24 | Registered primary was the proportion of patients with study-drug-related TEAEs, with no formal test: single doses 30 mg 1/13, 60 mg 3/10, 90 mg 3/8 vs pooled placebo 2/16; multidose 30 mg 8/16 vs placebo 0/7 (CT.gov posted results). | Weak signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 1/2 (1)
What this study did
Competitive landscape
Other Huntingtin (HTT) drugs
2 other tracked programmes target this mechanism, 1 of them ahead of this one.
This drug's own stage for Huntington's Disease: Phase 1/2. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| WVE-003: this drug | Phase 1/2 | RNA / oligonucleotide | Huntingtin (HTT) | Weak signal | NCT05032196: Registered primary was the proportion of patients with study-drug-related TEAEs, with no formal test: single doses 30 mg 1/13, 60 mg 3/10, 90 mg 3/8 vs pooled placebo 2/16; multidose 30 mg 8/16 vs placebo 0/7 (CT.gov posted results). | |
| Valbenazine (Ingrezza) | Approved | Small molecule | vesicular monoamine transporter 2 (VMAT2) | Partial signal | NCT04102579: Primary endpoint, change in UHDRS Total Maximal Chorea score (average of weeks 10 and 12): -4.6 with valbenazine vs -1.4 with placebo, treatment effect -3.2 units, p<0.0001 (INGREZZA label, KINECT-HD). | |
| Votoplam | Phase 3 | Small molecule | Huntingtin (HTT) | not yet graded | No reviewed efficacy summary in this indication | |
| Tanruprubart | Phase 2 | Monoclonal antibody | Complement C1q | not yet graded | No reviewed efficacy summary in this indication | |
| Ifezuntirgene Inilparvovec | Phase 1/2 | Gene therapy / editing | Huntingtin (HTT) gene | not yet graded | No reviewed efficacy summary in this indication | |
| Brezosiran | Phase 1 | RNA / oligonucleotide | Huntingtin (HTT) | not yet graded | No reviewed efficacy summary in this indication | |
| RG6662 | —(overall) | Gene therapy / editing | — | not yet graded | No reviewed efficacy summary in this indication |
Compare side by side
Upcoming events
No upcoming readouts on record for this asset.